Does govt have Rs 80,000 cr to buy, give out vaccine, Serum Inst chief asks

Experts say even as vaccine is being developed, govt should put in place its strategy for distribution and procurement instead of waiting for the vaccine to be ready

Adar Poonawalla, CEO, Serum Institute
Serum Institute of India is conducting the India trials for the coronavirus vaccine developed by Oxford-AstraZeneca - Covishield.
Ruchika Chitravanshi New Delhi
2 min read Last Updated : Sep 26 2020 | 5:49 PM IST
The chairman of Serum Institute of India, Pune Adar Poonawalla has estimated that the government would need to spend Rs 80,000 crore over the next one year to buy and distribute coronavirus vaccines to everyone in India. 

Questioning the health ministry and the Prime Minister’s Office in a tweet, Poonawalla said, “Quick question: will the government of India have 80,000 crores available, over the next one year? Because that's what @MoHFW_INDIA needs, to buy and distribute the vaccine to everyone in India. This is the next concerning challenge we need to tackle. 

Poonawala said, “I ask this question, because we need to plan and guide vaccine manufacturers both in India and overseas to service the needs of our country in terms of procurement and distribution.”

The expert group on vaccines chaired by V K Paul, member-health, Niti Aayog along with Rajesh Bhushan, Secretary, Ministry of Health and Family Welfare has met several times to deliberate over the financial resources required for the procurement of Covid-19 vaccine and various options of financing the same. The details of the government's plan have not been shared yet. 

Experts say that while the vaccine is under development, the government should use this time to put in place its strategy for distribution and procurement instead of waiting for the vaccine to be ready. 

Serum Institute of India is conducting the India trials for the coronavirus vaccine developed by Oxford-AstraZeneca - Covishield. 

The company has entered the phase three trials of the vaccine. It is among the three ongoing clinical trials for the coronavirus vaccine in India. Zydus Cadila and Bharat Biotech have completed the recruitments for the phase two trial.

The government is also in talks with Russia to facilitate trials for its vaccine Sputnik V in India and help them scale its manufacturing. 

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :Serum Institute of IndiaCoronavirus VaccineNiti Aayog

Next Story